NEXGEL, Inc. (NXGLW) stock
NXGLWNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as NXGL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 6/3072% below fair value
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $34.21MP/E –Yield –
Nexgel r&d expenses
Research and development expenses are spending on new products and technology.
Nexgel's R&D Expenses for the twelve months ending Sep 30, 2025 was $8.00K, down 91.2% year over year. For fiscal 2025 it was $2.00K, down 97.4% from the year before. The highest annual figure on record is $367.00K in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00K | -97.4% |
| FY2024 | Dec 31, 2024 | $78.00K | -24.3% |
| FY2023 | Dec 31, 2023 | $103.00K | -71.9% |
| FY2022 | Dec 31, 2022 | $367.00K | +1083.9% |
| FY2021 | Dec 31, 2021 | $31.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $20.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $7.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.00K | -50.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $76.00K | +38.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.00K | -93.1% |
| Q4 FY2023 | Dec 31, 2023 | $13.00K | -66.7% |
| Q3 FY2023 | Sep 30, 2023 | $6.00K | -96.9% |
| Q2 FY2023 | Jun 30, 2023 | $55.00K | -50.5% |
| Q1 FY2023 | Mar 31, 2023 | $29.00K | +20.8% |
| Q4 FY2022 | Dec 31, 2022 | $39.00K | +178.6% |
| Q3 FY2022 | Sep 30, 2022 | $193.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $111.00K | +1010.0% |
| Q1 FY2022 | Mar 31, 2022 | $24.00K | +242.9% |
| Q4 FY2021 | Dec 31, 2021 | $14.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $10.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $7.00K | – |